MedTrace Logo

L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy

NCT04268108 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2020-06-11

No results posted yet for this study

Summary

Safety and effectiveness of liquid tumor infiltrating lymphocytes in patients with advanced malignant tumors who have failed to anti-PD-1 therapy

Conditions

  • Advanced Solid Tumor

Interventions

BIOLOGICAL

liquid tumor infiltrating lymphocytes

Isolatation and amplification PD-1+ cells from peripheral blood lymphocytes under GMP conditions for clinical use.

Sponsors & Collaborators

  • Henan Cancer Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-02
Primary Completion
2022-02-19
Completion
2022-06-19

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04268108 on ClinicalTrials.gov